Rapalogs and mTOR inhibitors as anti-aging therapeutics.

Publication Type:

Review

Source:

The Journal of clinical investigation, Volume 123, Issue 3, p.980-9 (2013)

Keywords:

Agingdigestive disease, digestive deseases Animalsdigestive disease, digestive deseases Anti-Inflammatory Agentsdigestive disease, digestive deseases Antineoplastic Agentsdigestive disease, digestive deseases Autophagydigestive disease, digestive deseases Humansdigestive disease, digestive deseases Metformindigestive disease, digestive deseases Molecular Targeted Therapydigestive disease, digestive deseases Neoplasmsdigestive disease, digestive deseases Sirolimusdigestive disease, digestive deseases Stem Cellsdigestive disease, digestive deseases TOR Serine-Threonine Kinases

Abstract:

Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.